FRNM · Freenome, Inc. · Financials
$14.37
-0.42 (-2.84%)
At close · Sep 11
Going-concern doubt
— flagged Jul 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company's liquidity condition and mandatory liquidation raise substantial doubt about the Company's ability to continue as a going concern for a period of time within one year after the date that the accompanying unaudited condensed consolidated financial statements are issued. Management plans to address this uncertainty through a Business Combination. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after the Combination Period. The Company intends to complete the initial Business Combination before the end of the Combination Period. However, there can be no assurance that the Company will be able to consummate any Business Combination by the end of the Combination Period, including if the combination Period is further extended upon approval of the Extension Amendment Proposal.”View the 10-Q filed Jul 15, 2026
Market Cap
$148.20M
Shares
10.31M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
$837.47K
FY2025
Operating Cash Flow
-$864.65K
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 |
|---|---|---|
| — | $2.98M | |
| -$4.33M | -$2.98M | |
| $3.09M | $3.82M | |
| — | $3.82M | |
| -$762.63K | $837.47K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.86×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 11 similar-size Diagnostics & Research companies (of 48 listed).